VERVE THERAPEUTICS INC (VERV) Stock Overview
NASDAQ:VERV - US92539P1012 - Common Stock
VERV Key Statistics, Chart & Performance
The current stock price of VERV is 11.13 USD. In the past month the price decreased by -0.71%. In the past year, price increased by 50.41%.
VERV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.89 | 372.00B | ||
| AMGN | AMGEN INC | 13.47 | 158.13B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.77B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.32 | 101.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.92 | 62.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.56B | ||
| ARGX | ARGENX SE - ADR | 71.2 | 40.39B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.78 | 37.29B | ||
| INSM | INSMED INC | N/A | 27.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.66B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.7 | 20.42B |
Related stock screener links
About VERV
Company Profile
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company is headquartered in Boston, Massachusetts and currently employs 274 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels.
Company Info
VERVE THERAPEUTICS INC
201 Brookline Avenue, Suite 601
Boston MASSACHUSETTS US
CEO: Sekar Kathiresan
Employees: 255
Phone: 19785013026
VERVE THERAPEUTICS INC / VERV FAQ
What is the stock price of VERVE THERAPEUTICS INC today?
The current stock price of VERV is 11.13 USD. The price increased by 0.27% in the last trading session.
What is the ticker symbol for VERVE THERAPEUTICS INC stock?
The exchange symbol of VERVE THERAPEUTICS INC is VERV and it is listed on the Nasdaq exchange.
On which exchange is VERV stock listed?
VERV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VERVE THERAPEUTICS INC stock?
14 analysts have analysed VERV and the average price target is 13.26 USD. This implies a price increase of 19.14% is expected in the next year compared to the current price of 11.13. Check the VERVE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VERVE THERAPEUTICS INC worth?
VERVE THERAPEUTICS INC (VERV) has a market capitalization of 992.13M USD. This makes VERV a Small Cap stock.
How many employees does VERVE THERAPEUTICS INC have?
VERVE THERAPEUTICS INC (VERV) currently has 255 employees.
What are the support and resistance levels for VERVE THERAPEUTICS INC (VERV) stock?
VERVE THERAPEUTICS INC (VERV) has a support level at 11.11 and a resistance level at 11.31. Check the full technical report for a detailed analysis of VERV support and resistance levels.
Is VERVE THERAPEUTICS INC (VERV) expected to grow?
The Revenue of VERVE THERAPEUTICS INC (VERV) is expected to grow by 93.9% in the next year. Check the estimates tab for more information on the VERV EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VERVE THERAPEUTICS INC (VERV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VERV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VERV, evaluating the profitability, health, valuation and growth aspects
- VERVE THERAPEUTICS INC (VERV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VERVE THERAPEUTICS INC (VERV) Sales and EPS estimates to see what analysts future expectations are.
- VERVE THERAPEUTICS INC (VERV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VERVE THERAPEUTICS INC (VERV) Insider and Institutional Ownership to learn about the owners and their transactions.
- VERVE THERAPEUTICS INC (VERV) Stock Chart to make your own analysis
- VERVE THERAPEUTICS INC (VERV) Latest news and press-releases to stay up to date.
Does VERVE THERAPEUTICS INC (VERV) stock pay dividends?
VERV does not pay a dividend.
When does VERVE THERAPEUTICS INC (VERV) report earnings?
VERVE THERAPEUTICS INC (VERV) will report earnings on 2025-08-07, before the market open.
What is the Price/Earnings (PE) ratio of VERVE THERAPEUTICS INC (VERV)?
VERVE THERAPEUTICS INC (VERV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.11).
VERV Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to VERV. When comparing the yearly performance of all stocks, VERV is one of the better performing stocks in the market, outperforming 95.29% of all stocks.
VERV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VERV. VERV has a great financial health rating, but its profitability evaluates not so good.
VERV Financial Highlights
Over the last trailing twelve months VERV reported a non-GAAP Earnings per Share(EPS) of -2.11. The EPS increased by 26.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.47% | ||
| ROE | -38.23% | ||
| Debt/Equity | 0 |
VERV Forecast & Estimates
14 analysts have analysed VERV and the average price target is 13.26 USD. This implies a price increase of 19.14% is expected in the next year compared to the current price of 11.13.
For the next year, analysts expect an EPS growth of -8.2% and a revenue growth 93.9% for VERV